Vasculitis & polymyalgia rheumatica
Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab
Authors' conclusion
Vasculitic manifestations in the cranial vessels normalized after 52 weeks of treatment, whereas large vessel and PMR findings persisted despite lasting full remission.
Study context
- Population
- Patients with newly diagnosed GCA in the GUSTO trial
- Participants
- 18 patients
- Outcome
- Vasculitic and musculoskeletal MRI findings over time
Methodological detailsMRI substudy of the GUSTO trial, longitudinal, MRI at baseline (active, new-onset disease), weeks 24, 52 (remission on-treatment) and 104 (remission off-treatment)
- MRI substudy of the GUSTO trial
- Longitudinal
- MRI at baseline (active, new-onset disease), weeks 24, 52 (remission on-treatment) and 104 (remission off-treatment)
Main finding
As reported in the abstract
Vasculitic vessels still detectable in one in four cranial segments
week 24
No cranial vascular segment showed a vasculitic manifestation
weeks 52 and 104
Original publication
Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab. Rheumatology (Oxford). Published 22 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →